No Data
No Data
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BioLineRx Receives Nasdaq Minimum Bid Price Notification
Express News | BioLineRx To Present Poster On Economic Model Data For APHEXDA Today At ISPOR 2024
Buy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis Efficiency
Express News | BioLineRx Announces Poster Presentation On Apheresis Center Efficiency And CXCR4 Antagonists Including APHEXDA At ASFA 2024 Annual Meeting Apr. 17-19
Express News | BioLineRx Has Drawn-down The Second Tranche Of $20M Under Its Previously Announced $40M Non-Dilutive Debt Financing Agreement With Funds And Accounts Managed By Blackrock